Literature DB >> 23905811

HBV infection and hepatocellular carcinoma.

Massimo Iavarone1, Massimo Colombo.   

Abstract

The hepatitis B virus (HBV) plays a dominant role in the 749,000 new cases and 692,000 deaths related to hepatocellular carcinoma (HCC) that are estimated to occur each year worldwide. Chronic infection with HBV is responsible for 60% of HCCs in Asia and Africa and at least 20% of the tumors in Europe, Japan, and the United States. This article discusses the pathogenic role of HBV and the risk of HCC. Tumors almost invariably develop in the context of chronic hepatitis or cirrhosis, which makes early diagnosis the only practical approach to improve prognosis. The treatment options are also discussed.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hepatitis B; Hepatocellular carcinoma; Interferon; Nucleos(t)ide analogues; Surveillance

Mesh:

Substances:

Year:  2013        PMID: 23905811     DOI: 10.1016/j.cld.2013.05.002

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  13 in total

Review 1.  The role of microRNAs in hepatocyte metabolism and hepatitis B virus replication.

Authors:  Wanyu Deng; Mengji Lu
Journal:  Virol Sin       Date:  2016-12-28       Impact factor: 4.327

Review 2.  Viral hepatitis and hepatocellular carcinoma: etiology and management.

Authors:  Philippe J Zamor; Andrew S deLemos; Mark W Russo
Journal:  J Gastrointest Oncol       Date:  2017-04

3.  Classification and prediction of HCC tissues by Raman imaging with identification of fatty acids as potential lipid biomarkers.

Authors:  T Tolstik; C Marquardt; C Beleites; C Matthäus; C Bielecki; M Bürger; C Krafft; O Dirsch; U Settmacher; J Popp; A Stallmach
Journal:  J Cancer Res Clin Oncol       Date:  2014-09-20       Impact factor: 4.553

4.  A comparison of liver protection among 3-D conformal radiotherapy, intensity-modulated radiotherapy and RapidArc for hepatocellular carcinoma.

Authors:  Dong Chen; Renben Wang; Xiangjiao Meng; Tonghai Liu; Hongjiang Yan; Rui Feng; Shangang Liu; Shumei Jiang; Xiaoqing Xu; Kunli Zhu; Xue Dou
Journal:  Radiat Oncol       Date:  2014-02-06       Impact factor: 3.481

5.  Down-regulation of NTCP expression by cyclin D1 in hepatitis B virus-related hepatocellular carcinoma has clinical significance.

Authors:  Jingting Kang; Jie Wang; Jin Cheng; Zhiliang Cao; Ran Chen; Huiyu Li; Shuang Liu; Xiangmei Chen; Jianhua Sui; Fengmin Lu
Journal:  Oncotarget       Date:  2016-06-23

6.  Liver resection for young patients with large hepatocellular carcinoma: a single center experience from China.

Authors:  Xi-yu Liu; Jiang-feng Xu
Journal:  World J Surg Oncol       Date:  2014-06-03       Impact factor: 2.754

7.  Requirement of CRTC1 coactivator for hepatitis B virus transcription.

Authors:  Hei-Man Vincent Tang; Wei-Wei Gao; Chi-Ping Chan; Yun Cheng; Vidyanath Chaudhary; Jian-Jun Deng; Kit-San Yuen; Chun-Ming Wong; Irene Oi-Lin Ng; Kin-Hang Kok; Jie Zhou; Dong-Yan Jin
Journal:  Nucleic Acids Res       Date:  2014-10-09       Impact factor: 16.971

8.  The enhanced expression of death receptor 5 (DR5) mediated by HBV X protein through NF-kappaB pathway is associated with cell apoptosis induced by (TNF-α related apoptosis inducing ligand) TRAIL in hepatoma cells.

Authors:  Fanyun Kong; Hongjuan You; Jinjin Zhao; Wen Liu; Lei Hu; Wenya Luo; Wei Hu; Renxian Tang; Kuiyang Zheng
Journal:  Virol J       Date:  2015-11-17       Impact factor: 4.099

9.  Predictive factors for anti-HBs status after 1 booster dose of hepatitis B vaccine.

Authors:  I-Cheng Lu; Mei-Chu Yen Jean; Chi-Wei Lin; Wei-Hung Chen; Daw-Shyong Perng; Chih-Wen Lin; Hung-Yi Chuang
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

10.  Negative impact of hepatitis B surface seroclearance on prognosis of hepatitis B-related primary liver cancer.

Authors:  Cheng Lou; Tong Bai; Le-Wei Bi; Ying-Tang Gao; Zhi Du
Journal:  World J Clin Cases       Date:  2018-08-16       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.